vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Sabre Corp (SABR). Click either name above to swap in a different company.

Sabre Corp is the larger business by last-quarter revenue ($760.3M vs $493.8M, roughly 1.5× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 1.1%, a 5.8% gap on every dollar of revenue. On growth, Sabre Corp posted the faster year-over-year revenue change (8.3% vs -1.7%). Over the past eight quarters, Sabre Corp's revenue compounded faster (4.6% CAGR vs -0.1%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

Sabre Corporation, a travel technology company headquartered in Southlake, Texas, is the largest global distribution systems (GDS) provider for air bookings. The company's primary product, the Sabre Global Distribution System, and others like it, act as neutral intermediaries, connecting travel suppliers like airlines and hotels with travel sellers like agencies. They offer real-time availability and pricing, making them important for corporate travel management.

MD vs SABR — Head-to-Head

Bigger by revenue
SABR
SABR
1.5× larger
SABR
$760.3M
$493.8M
MD
Growing faster (revenue YoY)
SABR
SABR
+10.0% gap
SABR
8.3%
-1.7%
MD
Higher net margin
MD
MD
5.8% more per $
MD
6.8%
1.1%
SABR
Faster 2-yr revenue CAGR
SABR
SABR
Annualised
SABR
4.6%
-0.1%
MD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MD
MD
SABR
SABR
Revenue
$493.8M
$760.3M
Net Profit
$33.7M
$8.1M
Gross Margin
Operating Margin
9.9%
15.2%
Net Margin
6.8%
1.1%
Revenue YoY
-1.7%
8.3%
Net Profit YoY
10.5%
-77.0%
EPS (diluted)
$0.40
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
SABR
SABR
Q1 26
$760.3M
Q4 25
$493.8M
$592.0M
Q3 25
$492.9M
$715.2M
Q2 25
$468.8M
$687.1M
Q1 25
$458.4M
$776.6M
Q4 24
$502.4M
$575.6M
Q3 24
$511.2M
$691.3M
Q2 24
$504.3M
$695.0M
Net Profit
MD
MD
SABR
SABR
Q1 26
$8.1M
Q4 25
$33.7M
$-103.5M
Q3 25
$71.7M
$848.5M
Q2 25
$39.3M
$-256.5M
Q1 25
$20.7M
$35.5M
Q4 24
$30.5M
$-74.7M
Q3 24
$19.4M
$-62.8M
Q2 24
$-153.0M
$-69.8M
Gross Margin
MD
MD
SABR
SABR
Q1 26
Q4 25
55.4%
Q3 25
56.2%
Q2 25
56.9%
Q1 25
57.0%
Q4 24
58.8%
Q3 24
57.4%
Q2 24
57.8%
Operating Margin
MD
MD
SABR
SABR
Q1 26
15.2%
Q4 25
9.9%
1.6%
Q3 25
13.8%
13.1%
Q2 25
12.8%
13.0%
Q1 25
7.0%
13.3%
Q4 24
7.8%
6.5%
Q3 24
6.6%
8.4%
Q2 24
-31.3%
7.0%
Net Margin
MD
MD
SABR
SABR
Q1 26
1.1%
Q4 25
6.8%
-17.5%
Q3 25
14.5%
118.6%
Q2 25
8.4%
-37.3%
Q1 25
4.5%
4.6%
Q4 24
6.1%
-13.0%
Q3 24
3.8%
-9.1%
Q2 24
-30.3%
-10.0%
EPS (diluted)
MD
MD
SABR
SABR
Q1 26
$0.02
Q4 25
$0.40
$-0.08
Q3 25
$0.84
$1.98
Q2 25
$0.46
$-0.65
Q1 25
$0.24
$0.09
Q4 24
$0.37
$-0.20
Q3 24
$0.23
$-0.16
Q2 24
$-1.84
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
SABR
SABR
Cash + ST InvestmentsLiquidity on hand
$375.2M
$643.6M
Total DebtLower is stronger
$570.5M
$4.3B
Stockholders' EquityBook value
$865.9M
Total Assets
$2.2B
$4.3B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
SABR
SABR
Q1 26
$643.6M
Q4 25
$375.2M
$791.6M
Q3 25
$340.1M
$661.7M
Q2 25
$224.7M
$426.1M
Q1 25
$99.0M
$651.1M
Q4 24
$229.9M
$724.5M
Q3 24
$103.8M
$668.8M
Q2 24
$19.4M
$612.6M
Total Debt
MD
MD
SABR
SABR
Q1 26
$4.3B
Q4 25
$570.5M
$4.3B
Q3 25
$577.2M
$4.2B
Q2 25
$583.9M
$5.1B
Q1 25
$590.5M
$5.0B
Q4 24
$597.1M
$5.0B
Q3 24
$4.9B
Q2 24
$4.9B
Stockholders' Equity
MD
MD
SABR
SABR
Q1 26
Q4 25
$865.9M
$-1.0B
Q3 25
$890.7M
$-950.8M
Q2 25
$833.8M
$-1.8B
Q1 25
$789.2M
$-1.6B
Q4 24
$764.9M
$-1.6B
Q3 24
$732.5M
$-1.5B
Q2 24
$706.5M
$-1.5B
Total Assets
MD
MD
SABR
SABR
Q1 26
$4.3B
Q4 25
$2.2B
$4.5B
Q3 25
$2.2B
$4.4B
Q2 25
$2.1B
$4.4B
Q1 25
$2.0B
$4.7B
Q4 24
$2.2B
$4.6B
Q3 24
$2.1B
$4.7B
Q2 24
$2.0B
$4.7B
Debt / Equity
MD
MD
SABR
SABR
Q1 26
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
SABR
SABR
Operating Cash FlowLast quarter
$114.1M
Free Cash FlowOCF − Capex
$-155.4M
FCF MarginFCF / Revenue
-20.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
SABR
SABR
Q1 26
Q4 25
$114.1M
Q3 25
$137.3M
$33.7M
Q2 25
$137.2M
Q1 25
$-117.5M
$-80.6M
Q4 24
$133.0M
$75.7M
Q3 24
$91.8M
$24.4M
Q2 24
$107.0M
$38.2M
Free Cash Flow
MD
MD
SABR
SABR
Q1 26
$-155.4M
Q4 25
Q3 25
$13.4M
Q2 25
Q1 25
$-98.5M
Q4 24
$61.0M
Q3 24
$5.1M
Q2 24
$20.4M
FCF Margin
MD
MD
SABR
SABR
Q1 26
-20.4%
Q4 25
Q3 25
1.9%
Q2 25
Q1 25
-12.7%
Q4 24
10.6%
Q3 24
0.7%
Q2 24
2.9%
Capex Intensity
MD
MD
SABR
SABR
Q1 26
Q4 25
4.0%
Q3 25
2.8%
Q2 25
3.1%
Q1 25
2.3%
Q4 24
2.6%
Q3 24
2.8%
Q2 24
2.6%
Cash Conversion
MD
MD
SABR
SABR
Q1 26
Q4 25
3.39×
Q3 25
1.91×
0.04×
Q2 25
3.49×
Q1 25
-5.66×
-2.27×
Q4 24
4.36×
Q3 24
4.72×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

SABR
SABR

Marketplace$618.0M81%
Airline Technology$142.0M19%

Related Comparisons